Search results for "DASE"

showing 10 items of 1891 documents

COVID-19 and obesity: links and risks

2020

Applicable to the fields of endocrinology, as well as for specialists in cardiovascular disease (CVD), obesity has numerous cardiometabolic unfavorable consequences. Obesity is by far the leading c...

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismPneumonia ViralMEDLINEseverityDiseasePeptidyl-Dipeptidase ACOVID-19; Obesity; mortality; prognosis; severityCOVID-19BetacoronavirusMetabolic DiseasesRisk FactorsPandemicHumansMedicineObesityIntensive care medicinePandemicsbiologySARS-CoV-2business.industryViral EpidemiologyCOVID-19biology.organism_classificationmedicine.diseaseObesitymortalityPneumoniaAngiotensin-Converting Enzyme 2prognosisCoronavirus InfectionsbusinessBetacoronavirus
researchProduct

Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: Prospects for chemoprevention trials

2012

An involvement of oxidative stress (OS) was found in recent studies of Sjøgren's syndrome (SS) that reported significant changes in protein oxidation, myeloperoxidase activity, TNF-α, nitrotyrosine, and GSH levels in plasma from SS patients. Excess levels of OS markers, as oxidative DNA damage and propanoyl-lysine, were reported in saliva from SS patients. Previous reports concurred with a role of OS in SS pathogenesis, by showing a decreased expression of antioxidant activities in conjunctival epithelial cells of SS patients and in parotid gland tissue samples from SS patients. A link between OS and mitochondrial dysfunction (MDF) is recognized both on the grounds of the established role o…

medicine.medical_specialtyDNA damageMitochondrionBiologyProtein oxidationmedicine.disease_causeChemopreventionBiochemistryPathogenesischemistry.chemical_compoundInternal medicinemedicineHumansSalivaPeroxidasechemistry.chemical_classificationReactive oxygen speciesTumor Necrosis Factor-alphaNitrotyrosineAutoantibodyGeneral MedicineGlutathioneMitochondriaOxidative StressSjogren's SyndromeEndocrinologychemistryTyrosineBiomarkersOxidative stressDNA DamageFree Radical Research
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Incretin-based therapies in 2021 – Current status and perspectives for the future

2021

medicine.medical_specialtyDipeptidyl-Peptidase IV Inhibitorsbusiness.industryEndocrinology Diabetes and MetabolismMEDLINEIncretinDiabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents IncretinsIncretinsGlucagon-Like Peptide-1 ReceptorArticleEndocrinologyDiabetes Mellitus Type 2Internal medicinemedicineHumansHypoglycemic AgentsCurrent (fluid)Intensive care medicinebusiness
researchProduct

Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption

2000

Human serum contains two forms of tartrate-resistant acid phosphatase (TRAP), 5a and 5b. Of these, 5a contains sialic acid and 5b does not. We show here that antigenic properties and pH optimum of TRAP purified from human osteoclasts are identical to those of serum TRAP 5b and completely different from those of serum TRAP 5a, suggesting that 5b would be derived from osteoclasts and 5a from some other source. We developed a novel immunoassay specific for 5b using a monoclonal antibody O1A as capture antibody. O1A did not bind acid phosphatase derived from platelets and erythrocytes. Western analysis showed that O1A was specific for TRAP in both human bone and serum. We measured bound TRAP ac…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismAcid PhosphataseNeuraminidaseBone resorptionPlaceboschemistry.chemical_compoundDouble-Blind MethodReference ValuesOsteoclastInternal medicineEnzyme StabilitymedicineHumansOrthopedics and Sports MedicineBone ResorptionIncubationTartrate-resistant acid phosphataseEstradiolmedicine.diagnostic_testbiologyTartrate-Resistant Acid PhosphataseEstrogen Replacement TherapyAcid phosphataseAntibodies MonoclonalMiddle AgedSialic acidResorptionIsoenzymesPostmenopauseEndocrinologymedicine.anatomical_structurechemistryImmunoassaybiology.proteinFemaleNorethindroneBiomarkersJournal of Bone and Mineral Research
researchProduct

A 15-Year Perspective of the Fabry Outcome Survey

2016

Abstract The Fabry Outcome Survey (FOS) is an international long-term observational registry sponsored by Shire for patients diagnosed with Fabry disease who are receiving or are candidates for therapy with agalsidase alfa (agalα). Established in 2001, FOS provides long-term data on agalα safety/efficacy and collects data on the natural history of Fabry disease, with the aim of improving clinical management. The FOS publications have helped establish prognostic and severity scores, defined the incidence of specific disease variants and implications for clinical management, described clinical manifestations in special populations, confirmed the high prevalence of cardiac morbidity, and demon…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologyoutcomesFabry Outcome Survey03 medical and health sciences0302 clinical medicineInternal medicinemedicineGenetics (clinical)lcsh:R5-920agalsidase alfaFabry diseasebusiness.industryIncidence (epidemiology)Therapeutic effectEnzyme replacement therapymedicine.diseaseFabry diseaseNatural historyPediatrics Perinatology and Child HealthPhysical therapyObservational studybusinesslcsh:Medicine (General)Agalsidase alfa030217 neurology & neurosurgeryenzyme replacement therapy
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Pathophysiology of polymorphonuclear leukocyte in arterial hypertension

2009

This review shows how polymorphonuclear leukocytes (PMNs) play a pivotal role in the development of the organ injury that is associated with arterial hypertension. Elevated white blood cell count and higher levels of PMNs activation are risk factors for arterial hypertension and cardiovascular disease. Spontaneously activated PMNs release proinflammatory factors and reactive oxygen species, which have negative effects on vascular tone and on their adhesion to the endothelium. The oxidative stress in hypertensive PMNs is revealed by increased NADPH-oxidase production and lipid peroxidation and by decreased cytosolic and mitochondrial superoxide dismutase concentrations. The overexpression of…

medicine.medical_specialtyEndotheliumNeutrophilsPhysiologyPolymorphonuclear leukocyte Hypertension oxidative stress adhesion moleculesmedicine.disease_causeProinflammatory cytokineSuperoxide dismutaseLipid peroxidationLeukocyte Countchemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumansLeukocyte Rollingchemistry.chemical_classificationReactive oxygen speciesNADPH oxidasebiologySuperoxide Dismutasebusiness.industryCell adhesion moleculeNADPH OxidasesHematologymedicine.anatomical_structureEndocrinologychemistryCD18 AntigensHypertensionImmunologybiology.proteinLipid PeroxidationCardiology and Cardiovascular MedicinebusinessOxidative stressClinical Hemorheology and Microcirculation
researchProduct

Sirolimus-Induced Vascular Dysfunction

2008

Objectives This study sought to analyze mechanisms that mediate vascular dysfunction induced by sirolimus. Background Despite excellent antirestenotic capacity, sirolimus-eluting stents have been found to trigger coronary endothelial dysfunction and impaired re-endothelialization. Methods To mimic the continuous sirolimus exposure of a stented vessel, Wistar rats underwent drug infusion with an osmotic pump for 7 days. Results Sirolimus treatment caused a marked degree of endothelial dysfunction as well as a desensitization of the vasculature to the endothelium-independent vasodilator nitroglycerin. Also, sirolimus stimulated intense transmural superoxide formation as detected by dihydroeth…

medicine.medical_specialtyEndotheliumVasodilationNitric oxidechemistry.chemical_compoundInternal medicinemedicinecardiovascular diseasesEndothelial dysfunctionNADPH oxidaseNicotinamidebiologybusiness.industrySuperoxideequipment and suppliesmedicine.diseasesurgical procedures operativemedicine.anatomical_structureEndocrinologychemistrySirolimuscardiovascular systembiology.proteinCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

Dissociation of airway responsiveness and bronchoalveolar lavage (BAL) cell composition in sensitized guinea-pigs after daily inhalation of ovalbumin

1994

Summary. The association between inflammatory cell influx, cell activation status and change of airway responsiveness to acelylcholine (ACh) after daily inhalation of ovalbumin (OA) in sensitized guinea–pigs was investigated. Starting 3 weeks after sensitization (OA at 50mg/kg s.c. + i.p.) guinea–pigs were exposed daily to 2% OA (10min: undercover of 0.5Smg/kg mepyramine i.p. 15min before OA) for 2 weeks. Concentration–response curves (CRCs) for inhaled ACh were performed 24 h after the last OA–challenge and 24 h after another single OA–inhalation 1 week later. CRCs for inhaled ACh were neither affected 24 h after the last OA challenge (daily for two weeks) nor 24 h after another OA–inhalat…

medicine.medical_specialtyEosinophil PeroxidaseOvalbuminGuinea PigsImmunologyMepyramineBronchiLeukocyte CountInternal medicineAdministration InhalationmedicineAnimalsImmunology and AllergyRespiratory systemSensitizationPeroxidasemedicine.diagnostic_testbiologyInhalationbusiness.industryAcetylcholineOvalbuminmedicine.anatomical_structureBronchoalveolar lavageEndocrinologyPeroxidasesMethylprednisoloneImmunologybiology.proteinFemaleImmunizationBronchial HyperreactivitybusinessCell activationBronchoalveolar Lavage Fluidmedicine.drugClinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy
researchProduct